Abstract
Endothelial dysfunction (EtD) has emerged as a critical master pathway in the pathogenesis of both vascular disease and erectile dysfunction (ED). Drugs that have been developed for vascular diseases and/or found to have beneficial endothelial effects may be helpful in the management of ED. In this manuscript we summarize the current state of the art with respect to endothelial active drugs and discuss the evidence supporting their use in the management of ED. Pubmed query for the terms Endothelial dysfunction, erectile dysfunction, pharmaceuticals, “endothelium”, “function”, “pharmaceutical”, “eNOS”, “erectile dysfunction” and “erectile function” was conducted. Relevant articles were reviewed and summarized. A variety of cardiovascular medications have mechanisms of action that involve the endothelium. Examples include HMG-CoA Reductase inhibitors (“statins”), Angiotensin Converting Enzyme Inhibitors (ACEI), Angiotensin Receptor blockers (ARB), Endothelin Receptor Antagonists (ERA), certain beta blockers, and some oral hypoglycemics. Some of these drugs have been found to improve penile erection, although an endothelium dependent mechanism has not been conclusively demonstrated in all studies. Drugs that improve endothelial function in the cavernous arteries and the erectile tissues of the corpora cavernosa hold great promise in treating or at least minimizing the vascular damage that contributes to ED. ACEI and ARB appear to hold great promise in this regard, while statins and oral hypoglycemics may play a potentially useful role as adjunctive therapy for ED. Improvements in endothelial function may help reverse ED in some cases, which would be a marked improvement over management with currently available “on demand” ED therapies.
Keywords: Endothelium, erectile dysfunction, nitric oxide, eNOS, vascular disease, drugs
Current Pharmaceutical Design
Title: Drugs Designed to Improve Endothelial Function: Effects on Erectile Dysfunction
Volume: 14 Issue: 35
Author(s): A. W. Shindel, S. Kishore and T. F. Lue
Affiliation:
Keywords: Endothelium, erectile dysfunction, nitric oxide, eNOS, vascular disease, drugs
Abstract: Endothelial dysfunction (EtD) has emerged as a critical master pathway in the pathogenesis of both vascular disease and erectile dysfunction (ED). Drugs that have been developed for vascular diseases and/or found to have beneficial endothelial effects may be helpful in the management of ED. In this manuscript we summarize the current state of the art with respect to endothelial active drugs and discuss the evidence supporting their use in the management of ED. Pubmed query for the terms Endothelial dysfunction, erectile dysfunction, pharmaceuticals, “endothelium”, “function”, “pharmaceutical”, “eNOS”, “erectile dysfunction” and “erectile function” was conducted. Relevant articles were reviewed and summarized. A variety of cardiovascular medications have mechanisms of action that involve the endothelium. Examples include HMG-CoA Reductase inhibitors (“statins”), Angiotensin Converting Enzyme Inhibitors (ACEI), Angiotensin Receptor blockers (ARB), Endothelin Receptor Antagonists (ERA), certain beta blockers, and some oral hypoglycemics. Some of these drugs have been found to improve penile erection, although an endothelium dependent mechanism has not been conclusively demonstrated in all studies. Drugs that improve endothelial function in the cavernous arteries and the erectile tissues of the corpora cavernosa hold great promise in treating or at least minimizing the vascular damage that contributes to ED. ACEI and ARB appear to hold great promise in this regard, while statins and oral hypoglycemics may play a potentially useful role as adjunctive therapy for ED. Improvements in endothelial function may help reverse ED in some cases, which would be a marked improvement over management with currently available “on demand” ED therapies.
Export Options
About this article
Cite this article as:
Shindel W. A., Kishore S. and Lue F. T., Drugs Designed to Improve Endothelial Function: Effects on Erectile Dysfunction, Current Pharmaceutical Design 2008; 14 (35) . https://dx.doi.org/10.2174/138161208786898752
DOI https://dx.doi.org/10.2174/138161208786898752 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
Blood-based biomarkers in large-scale screening for neurodegenerative diseases
Disease biomarkers are necessary tools that can be employ in several clinical context of use (COU), ranging from the (early) diagnosis, prognosis, prediction, to monitor of disease state and/or drug efficacy. Regarding neurodegenerative diseases, in particular Alzheimer’s disease (AD), a battery of well-validated biomarkers are available, such as cerebrospinal fluid ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Diabetes mellitus: advances in diagnosis and treatment driving by precision medicine
Diabetes mellitus (DM) is a chronic degenerative metabolic disease with ever increasing prevalence worldwide which is now an epidemic disease affecting 500 million people worldwide. Insufficient insulin secretion from pancreatic β cells unable to maintain blood glucose homeostasis is the main feature of this disease. Multifactorial and complex nature of ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Current Management of Intermittent Claudication: The Role of Pharmacological and Nonpharmacological Symptom-Directed Therapies
Current Vascular Pharmacology Nanoparticle Mediated Gene Therapy: A Trailblazer Armament to Fight CNS Disorders
Current Medicinal Chemistry Cellular Balance, Genes,and the Huang Ti Nei Ching Su Wen
Current Neurovascular Research Current Development in Tissue-Engineered Vascular Grafts
Vascular Disease Prevention (Discontinued) Harnessing the Prevention Benefits of Antiretroviral Therapy to Address HIV and Tuberculosis
Current HIV Research Clinical Pharmacogenetics in Oncology: the Paradigm of Molecular Targeted Therapies
Current Pharmaceutical Design Leptin and the Cardiovascular System: A Review
Recent Patents on Cardiovascular Drug Discovery Diagnostic and Therapeutic Uses of Nanomaterials in the Brain
Current Medicinal Chemistry Role of Physician Gender in the Quality of Care of Cardiometabolic Diseases
Current Pharmaceutical Design Therapeutic Approach on AGE-RAGE Interaction and Its Function in Diabetic Inflammation Process
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Recent Advancements in Diagnosis and Therapy of Liver Cirrhosis
Current Drug Targets Major Challenges for Gene Therapy of Thalassemia and Sickle Cell Disease
Current Gene Therapy Brain SPECT with Perfusion Radiopharmaceuticals and Dopaminergic System Radiocompounds in Dementia Disorders
Current Alzheimer Research Role of Advanced Glycation End Products (AGEs) in Osteoporosis in Diabetes
Current Drug Targets Distinct Biomarkers for Early Diagnosis of Diabetic Nephropathy
Current Diabetes Reviews Editorial [PCI and Stable Coronary Heart Disease - COURAGE to Change Our Minds?]
Current Vascular Pharmacology NPY and NPY Receptors in Vascular Remodeling
Current Topics in Medicinal Chemistry Peripheral Immunity, Immunoaging and Neuroinflammation in Parkinson’s Disease
Current Medicinal Chemistry Pathogenesis and Therapeutics of Interstitial Lung Disease in Systemic Sclerosis
Current Rheumatology Reviews Prognostic Value of Coronary Artery Calcification
Vascular Disease Prevention (Discontinued)